mCNV
Strong, rapid, and sustained visual gains over 48 weeks
MOST VISUAL GAINS WERE ACHIEVED WITH 1 OR 2 INJECTIONS
EYLEA® 2mg-treated patients had a mean gain of +12.1 letters and 39% gained ≥3 lines at Week 24,increasing to +13.5 letters and 50% with ≥3 lines gained at Week 48
WEEK 48
Mean change in BCVA through Week 100
EYLEA® 2mg administered at baseline and monthly up to Week 44 if mCNV persisted or recurred; n=90.- Sham injection administered at baseline up to Week 20 regardless of whether re-treatment criteria were fulfilled or not, followed by EYLEA® 2mg at Week 24 and monthly if disease persisted/recurred up to Week 44; n=31.
- mCNV lesion size was reduced by >50% from baseline to Week 24 in the early EYLEA® 2mg treatment group.
- Lesion size almost doubled in the delayed treatment group.
- mCNV leakage was resolved by Week 48 in 86% of early EYLEA® 2mg-treated patients vs. 67% in the delayed treatment group.
BCVA, best-corrected visual acuity; mCNV, myopic choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; RCT, randomized controlled trial; VA, visual acuity.
PP-EYL-IL-0128-1